Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.69 |
| ▸ | GRM5 | P41594 | 15/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272755 | 0.96 | NR1H4 (0.68) | NR1H4GRM5HCRTR1HCRTR2MAPT | |
| SCHEMBL8272720 | 0.96 | NR1H4 (0.68) | NR1H4GRM5HCRTR1HCRTR2MAPT | |
| SCHEMBL8245030 | 0.96 | NR1H4 (0.68) | NR1H4GRM5HCRTR1HCRTR2MAPT | |
| Hydrochloric Acid SCHEMBL4956639 | 0.95 | NR1H4 (0.67) | NR1H4GRM5HCRTR1HCRTR2MAPT | |
| Hydrochloric Acid SCHEMBL4955423 | 0.95 | NR1H4 (0.67) | NR1H4GRM5HCRTR1HCRTR2MAPT | |
| Hydrochloric Acid SCHEMBL4955420 | 0.95 | NR1H4 (0.67) | NR1H4GRM5HCRTR1HCRTR2MAPT | |
| SCHEMBL8242963 | 0.85 | NR1H4 (0.69) | NR1H4GRM5 | |
| SCHEMBL8236561 | 0.85 | NR1H4 (0.69) | NR1H4GRM5 | |
| SCHEMBL8242912 | 0.85 | NR1H4 (0.69) | NR1H4GRM5 | |
| SCHEMBL1061407 | 0.84 | NR1H4 (0.74) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101437798-A | Mglur5 modulators II | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | claimed |
| EP-2027090-A2 | MGLUR5 MODULATORS II | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130821-A2 | MGLUR5 MODULATORS II | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| WO-2007130821-A2 | MGLUR5 MODULATORS II | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| WO-2007039781-A2 | NEW COMPOUNDS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259916-A1 | mGluR5 modulators II | GRM5, GRM2, GRIK5 | NR1H4 299/4885GRM5 1/4885HCRTR1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.